Effectiveness of Posluma PET Scan for Post-Treatment Monitoring of Prostate Cancer

Starting soon · Phase 2

Conditions studied: Prostate Cancer

In brief

To determine the effectiveness of Posluma PET Scan for monitoring prostate cancer patients after targeted treatment, including how accurately it can detect any remaining or returning cancer after about 12 months post-treatment.

Key facts

Study ID

NCT07733908

Run by

Aditya Bagrodia

People needed

22

Starts

2026-08-01

Expected to finish

2030-07-01

Last updated by the study team

2026-07-29

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis: Histologically confirmed PCa.
• Risk Profile: Intermediate-risk , organ-confined PCa
• Eligibility for Focal Therapy: Determined to be an appropriate candidate for focal therapy based on clinical evaluation.
• Age: 18 years or older.
• Life Expectancy: Expected survival of at least 10 years.
• Informed Consent: Ability to understand and willingness to sign the informed consent form.

You may not qualify if…

• Previous Treatment: Prior treatment for PCa, including radiation therapy, chemotherapy, focal therapy, or androgen deprivation therapy.
• Severe Comorbid Conditions: Presence of severe comorbid conditions that may interfere with study participation, such as uncontrolled cardiovascular, renal, hepatic, or metabolic diseases.
• Contraindications to Imaging: Known hypersensitivity to components of the Posluma PSMA radiotracer, or inability to undergo PET or MRI imaging due to medical or anatomical constraints (e.g., severe claustrophobia, metallic implants incompatible with MRI).

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.